drugset / Trial / NCT06760481

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

NCT06760481

Phase 1 Active not recruiting 7 enrolled M.D. Anderson Cancer Center
RandomizedSingle-groupOpen-labelTreatment

Summary

An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies.

Timeline

Start
2025-04-13
Primary completion
2028-09-15
Completion
2030-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiragolumab Monoclonal antibody Intravenous
Background Atezolizumab Monoclonal antibody Intravenous